Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY27 results · Apr–Jun 2026
Aarti Drugs reported revenue from operations of ₹702.78 crore (up 19.0% from Q1 FY26) and net profit of ₹50.13 crore (down 7.1% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 702.78 | 590.51 | +19.0% | 720.30 | −2.4% |
| Other income | 0.81 | 0.31 | +161.3% | 0.76 | +6.6% |
| Total income | 703.59 | 590.82 | +19.1% | 721.06 | −2.4% |
| Profit before tax | 69.24 | 51.11 | +35.5% | 70.36 | −1.6% |
| Net profit for the period | 50.13 | 53.97 | −7.1% | 55.26 | −9.3% |
| Attributable to shareholders of the company | 50.17 | 53.91 | −6.9% | 55.19 | −9.1% |
| EPS, basic (₹) | 5.49 | 5.91 | −7.1% | 6.05 | −9.3% |
| Net margin (%) | 7.1 | 9.1 | 7.7 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 627.45 | 520.96 | +20.4% | 631.68 | −0.7% |
| Other income | 0.20 | 0.38 | −47.4% | 0.83 | −75.9% |
| Total income | 627.65 | 521.34 | +20.4% | 632.51 | −0.8% |
| Profit before tax | 67.85 | 45.25 | +49.9% | 58.56 | +15.9% |
| Net profit for the period | 50.85 | 48.64 | +4.5% | 44.96 | +13.1% |
| EPS, basic (₹) | 5.57 | 5.33 | +4.5% | 4.93 | +13.0% |
| Net margin (%) | 8.1 | 9.3 | 7.1 |
Consolidated
- Filed with BSE
- 31 Jul 2026, 20:41 IST
- Board meeting
- 31 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2026, 20:41 IST
- Board meeting
- 31 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Audited
- Source
- XBRL filing on BSE